NO961859L - In situ modifikasjon og manipulering av stamceller fra sentralnervesystemet - Google Patents
In situ modifikasjon og manipulering av stamceller fra sentralnervesystemetInfo
- Publication number
- NO961859L NO961859L NO961859A NO961859A NO961859L NO 961859 L NO961859 L NO 961859L NO 961859 A NO961859 A NO 961859A NO 961859 A NO961859 A NO 961859A NO 961859 L NO961859 L NO 961859L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- situ
- stem cells
- manipulation
- nervous system
- Prior art date
Links
- 238000011065 in-situ storage Methods 0.000 title abstract 4
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 239000002243 precursor Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003102 growth factor Substances 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14950893A | 1993-11-09 | 1993-11-09 | |
PCT/CA1994/000614 WO1995013364A1 (en) | 1993-11-09 | 1994-11-08 | In situ modification and manipulation of stem cells of the central nervous system |
Publications (3)
Publication Number | Publication Date |
---|---|
NO961859D0 NO961859D0 (no) | 1996-05-08 |
NO961859L true NO961859L (no) | 1996-07-03 |
NO317724B1 NO317724B1 (no) | 2004-12-13 |
Family
ID=22530608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19961859A NO317724B1 (no) | 1993-11-09 | 1996-05-08 | In situ modifikasjon og manipulering av stamceller fra sentralnervesystemet |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0728194B1 (no) |
JP (1) | JP3952508B2 (no) |
CN (1) | CN1141058A (no) |
AT (1) | ATE230795T1 (no) |
AU (1) | AU697894B2 (no) |
CA (1) | CA2175992C (no) |
DE (1) | DE69431993T2 (no) |
DK (1) | DK0728194T3 (no) |
ES (1) | ES2189807T3 (no) |
FI (1) | FI120455B (no) |
NO (1) | NO317724B1 (no) |
WO (1) | WO1995013364A1 (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10509592A (ja) * | 1994-11-14 | 1998-09-22 | ニューロスフィアーズ ホウルディングス リミテッド | 神経幹細胞増殖調節 |
WO1997035605A1 (en) * | 1996-03-26 | 1997-10-02 | Neurospheres Holdings Ltd. | Manipulation of mitotically active cells of the hippocampal region of the brain |
US7544511B2 (en) | 1996-09-25 | 2009-06-09 | Neuralstem Biopharmaceuticals Ltd. | Stable neural stem cell line methods |
US6787355B1 (en) | 1996-08-26 | 2004-09-07 | Mcgill University | Multipotent neural stem cells from peripheral tissues and uses thereof |
US6969608B1 (en) | 1996-08-26 | 2005-11-29 | Mcgill University | Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors |
CA2216439A1 (en) * | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Pharmaceuticals containing retinal stem cells |
EP0941109A1 (en) * | 1996-11-15 | 1999-09-15 | Neurospheres Holdings Ltd. | Pretreatment with growth factors to protect against cns damage |
US20020123143A1 (en) | 1997-08-22 | 2002-09-05 | Jean Toma | Multipotent stem cells from peripheral tissues and uses thereof |
US6093531A (en) * | 1997-09-29 | 2000-07-25 | Neurospheres Holdings Ltd. | Generation of hematopoietic cells from multipotent neural stem cells |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
US6541247B1 (en) | 1998-06-25 | 2003-04-01 | Neuronova Ab | Method of isolating ependymal neural stem cells |
SE9802264D0 (sv) | 1998-06-25 | 1998-06-25 | Neuronova Ab | A method of isolating cells |
US7544509B2 (en) | 2000-01-24 | 2009-06-09 | Mcgill University | Method for preparing stem cell preparations |
ATE473751T1 (de) | 2000-02-11 | 2010-07-15 | Schepens Eye Res Inst | Isolierung und transplantation von retinalen stammzellen |
WO2002069975A1 (en) * | 2001-03-02 | 2002-09-12 | Stem Cell Therapeutics Inc. | Use of estrogen to induce neural stem cell increase |
AR036400A1 (es) | 2001-08-30 | 2004-09-08 | Stem Cell Therapeutics Inc | Regulacion combinada de la produccion de celulas nerviosas. |
WO2003024472A2 (en) | 2001-09-14 | 2003-03-27 | Stem Cell Therapeutics Inc. | Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof |
JP4623967B2 (ja) | 2002-01-14 | 2011-02-02 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 幹細胞の移動および増殖を促進するための修飾されたピリミジン化合物の使用 |
US7704737B2 (en) * | 2002-07-30 | 2010-04-27 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
US20040185429A1 (en) | 2002-12-09 | 2004-09-23 | Judith Kelleher-Andersson | Method for discovering neurogenic agents |
US8293488B2 (en) | 2002-12-09 | 2012-10-23 | Neuralstem, Inc. | Method for screening neurogenic agents |
US8093205B2 (en) | 2003-12-01 | 2012-01-10 | Medtronic, Inc. | Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis |
AU2005211847B2 (en) * | 2004-02-13 | 2011-02-24 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (LH) and chorionic gonadotropin (hCG) for proliferation of neural stem cells and neurogenesis |
RU2434636C2 (ru) | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Трансплантация нервных клеток для лечения нейродегенеративных состояний |
KR20080074108A (ko) | 2005-09-27 | 2008-08-12 | 스템 셀 테라퓨틱스 코포레이션 | 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식 |
KR20080106976A (ko) | 2006-03-17 | 2008-12-09 | 스템 셀 테라퓨틱스 코포레이션 | 신경 줄기 세포 증식제 및 신경 줄기 세포 분화제의 연속 투여 방법 |
WO2008093827A1 (ja) * | 2007-02-01 | 2008-08-07 | Osaka Industrial Promotion Organization | 中枢神経障害治療剤及び中枢神経障害の治療方法 |
JP2009278873A (ja) * | 2008-05-19 | 2009-12-03 | Japan Health Science Foundation | 培地および培養方法 |
AU2011282642B2 (en) | 2010-07-28 | 2015-06-11 | Shinn-Zong Lin | Methods for treating and/or reversing neurodegenerative diseases and/or disorders |
CA2864818C (en) | 2012-02-17 | 2022-05-03 | The Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
WO2014157047A1 (ja) * | 2013-03-27 | 2014-10-02 | 千葉県 | 神経変性疾患治療剤 |
EP3209306B1 (en) | 2014-10-20 | 2024-04-24 | Neuralstem, Inc. | Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof |
AU2015336453B2 (en) | 2014-10-24 | 2021-05-20 | Riken | Production method for nerve tissue |
CA3021828A1 (en) * | 2016-04-22 | 2017-10-26 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing retinal tissue |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
US5034375A (en) * | 1988-08-10 | 1991-07-23 | Institute Of Molecular Biology, Inc. | Process of wound healing using PDGF and EGF |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
IT1240683B (it) * | 1990-04-26 | 1993-12-17 | Zambon Spa | Composizione farmaceutica contenente egf |
JPH04224522A (ja) * | 1990-04-27 | 1992-08-13 | Merck & Co Inc | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 |
WO1993008825A1 (en) * | 1991-11-04 | 1993-05-13 | Zymogenetics, Inc. | Pdgf gel formulation |
JP3583778B2 (ja) * | 1993-01-29 | 2004-11-04 | ニューロスフィアーズ ホウルディングス リミテッド | 神経幹細胞の遺伝子修飾 |
-
1994
- 1994-11-08 DK DK94931482T patent/DK0728194T3/da active
- 1994-11-08 ES ES94931482T patent/ES2189807T3/es not_active Expired - Lifetime
- 1994-11-08 AU AU80561/94A patent/AU697894B2/en not_active Ceased
- 1994-11-08 CN CN94194785A patent/CN1141058A/zh active Pending
- 1994-11-08 DE DE69431993T patent/DE69431993T2/de not_active Expired - Lifetime
- 1994-11-08 EP EP94931482A patent/EP0728194B1/en not_active Expired - Lifetime
- 1994-11-08 JP JP51349995A patent/JP3952508B2/ja not_active Expired - Fee Related
- 1994-11-08 AT AT94931482T patent/ATE230795T1/de active
- 1994-11-08 CA CA002175992A patent/CA2175992C/en not_active Expired - Fee Related
- 1994-11-08 WO PCT/CA1994/000614 patent/WO1995013364A1/en active IP Right Grant
-
1996
- 1996-04-30 FI FI961855A patent/FI120455B/fi not_active IP Right Cessation
- 1996-05-08 NO NO19961859A patent/NO317724B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FI961855A (fi) | 1996-06-04 |
NO961859D0 (no) | 1996-05-08 |
AU8056194A (en) | 1995-05-29 |
FI120455B (fi) | 2009-10-30 |
WO1995013364A1 (en) | 1995-05-18 |
CN1141058A (zh) | 1997-01-22 |
JP3952508B2 (ja) | 2007-08-01 |
AU697894B2 (en) | 1998-10-22 |
NO317724B1 (no) | 2004-12-13 |
CA2175992A1 (en) | 1995-05-18 |
EP0728194A1 (en) | 1996-08-28 |
DE69431993T2 (de) | 2003-11-27 |
ATE230795T1 (de) | 2003-01-15 |
FI961855A0 (fi) | 1996-04-30 |
DE69431993D1 (de) | 2003-02-13 |
ES2189807T3 (es) | 2003-07-16 |
DK0728194T3 (da) | 2003-04-22 |
EP0728194B1 (en) | 2003-01-08 |
CA2175992C (en) | 2008-04-01 |
JPH09507747A (ja) | 1997-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO961859D0 (no) | In situ modifikasjon og manipulering av stamceller fra sentralnervesystemet | |
DK1226233T3 (da) | Multipotente voksne stamceller og fremgangsmåder til isolering heraf | |
GB9308271D0 (en) | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method | |
ATE286126T1 (de) | Glialmitogene faktoren, ihre herstellung und verwendung | |
DK0395355T3 (da) | Frigivelse af celler fra affinitetsmatricer | |
SG152273A1 (en) | Pdx1 expressing endoderm | |
DE69937888D1 (de) | Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen | |
DE69232687D1 (de) | Rezeptor flk-2 von pluripotenten hämatopoetischen Stammzellen | |
NO20001509L (no) | Dannelse av hematopoetiske celler fra multipotente neurale stam-celler | |
ATE288481T1 (de) | Verwendung von collagenase in der zubereitung von neuralen stammzellkulturen | |
ATE154245T1 (de) | Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen | |
DK0783693T3 (da) | In vitro-modeller for CNS-funktion og -dysfunktion | |
ATE473273T1 (de) | Angereicherte zellpopulationen des zentralen nervensystems | |
ATE285177T1 (de) | Thiole zur förderung des wachstumsvon hömatopoietischen vorläuferzellen | |
ES8605857A1 (es) | Procedimiento para la obtencion de la enzima lignolitica pa-ra cultivo de microorganismos provinientes de la phanero- chaete chrysosporium | |
DE60039160D1 (de) | Verwendung von erbb-rezeptorliganden zur behandlung von diabetes | |
EP0244361A3 (en) | Individual beta-form crystals of tetrakis-û3-(3,5-di-t-butyl-4-hydroxyphenyl)-propionyloxymethyl¨ methane and process for their manufacture | |
NO180531C (no) | Fremgangsmåte og anlegg for tilvirkning av råstoff-briketter for fremstilling av silisium, silisiumkarbid eller ferrosilisium | |
DK1007647T3 (da) | Höjniveauekspression af INGAP | |
ATE22010T1 (de) | Antipsychotische trans-dihydrolisuride. | |
GB906272A (en) | Improvements in or relating to the manufacture of handles for ceramic ware | |
GB982659A (en) | Improvements in or relating to smokers' ash-trays | |
IL143403A0 (en) | Methods and compositions for treating disorders involving excitotoxicity | |
RO97107B1 (ro) | Mortar carbonic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |